Subscribe or Manage Preferences
VBCN - November 2016 Volume 3, No 3 - FDA News & Updates

Abuse-Deterrent Troxyca ER Approved for Chronic Pain

On August 19, 2016, the FDA approved an extended release, abuse-deterrent combination of oxycodone hydrochloride plus naltrexone hydrochloride (Troxyca ER; Pfizer) capsules for the treatment of pain that is severe enough to require daily, around-the-clock, long-term opioid therapy and for which alternative treatment options are inadequate.

This combination of an opioid agonist and an opioid antagonist capsule consists of an extended release formulation of oxycodone “pellet” that surrounds a naltrexone core. When taken as directed, the naltrexone is intended to remain sequestered and patients receive oxycodone in an extended release manner. If the medication is crushed, naltrexone will be released and can counteract oxycodone’s effects.

The efficacy of oxycodone hydrochloride plus naltrexone hydrochloride extended release capsules was evaluated in one randomized, double-blind, placebo-controlled clinical trial involving 281 patients with moderate-to-severe chronic low back pain who received the combination drug or placebo.

Overall, 58% of patients who received the combination drug had a ≥30% decrease in their weekly average numeric rating scale-pain intensity scores versus 44% of patients who received placebo. Furthermore, 40% of patients who received the combination drug had a 50% decrease in the numeric rating scale-pain intensity scores versus 30% of patients who received placebo.

“Public health authorities and regulators have encouraged the development of treatments that are more difficult to abuse, yet offer pain relief to appropriate patients when used as indicated,” said Rory O’Connor, MD, Chief Medical Officer of Internal Medicine at Pfizer. “The development of this medication with abuse-deterrent properties is another example of our ongoing commitment to advancing science and the treatment of patients with pain conditions.”

The most common adverse reactions reported with the use of oxycodone hydrochloride plus naltrexone hydrochloride extended release capsules included nausea, constipation, vomiting, headache, and somnolence.

Related Items
FDA News - October 2017
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in FDA News & Updates
Scott Gottlieb, MD, Appointed as New FDA Commissioner
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in FDA News & Updates
New Drugs Approved for Giant-Cell Arteritis and Moderate-to-Severe Rheumatoid Arthritis
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in FDA News & Updates
FDA Releases Draft Guidances on Sharing Healthcare Economic Information, Industry Communication Regulations
Leslie Wyatt
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in FDA News & Updates
FDA News - December 2016
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in FDA News & Updates
FDA Approves First Tissue-Engineered Autologous Cellularized Scaffold Product for the Repair of Cartilage Defects
In the News: Value-Based Care - December 2016 published on December 15, 2016 in FDA News & Updates
Abuse-Deterrent Oxycodone Extended-Release Capsules Approved for Chronic Pain
In the News: Value-Based Care - November 2016 published on November 7, 2016 in FDA News & Updates
FDA News - October 2016
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in FDA News & Updates
Adalimumab Biosimilar Approved for Multiple Inflammatory Indications
In the News: Value-Based Care - September 2016 published on September 27, 2016 in FDA News & Updates
Biosimilar to Etanercept FDA Approved for Inflammatory Diseases
In the News: Value-Based Care - September 2016 published on September 12, 2016 in FDA News & Updates
Last modified: November 30, 2016
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology